公开(公告)号：US20180297994A1

公开(公告)日：2018-10-18

申请号：US15735138

申请日：2016-06-06

申请人： Bayer Pharma Aktiengesellschaft

发明人： Henrik TELLER ,  Alexander STRAUB ,  Markus BRECHMANN ,  Thomas MÜLLER ,  Mark MEININGHAUS ,  Katrin NOWAK-REPPEL ,  Hanna TINEL ,  Klaus MÜNTER ,  Daniela FLIEGNER ,  Thomas MONDRITZKI ,  Melissa BOULTADAKIS ARAPINIS ,  Tobias MARQUARDT ,  Alexandros VAKALOPOULOS ,  Anne-Sophie REBSTOCK ,  Matthias Beat WITTWER

IPC分类号： C07D471/04 ,  A61P9/04 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  C07D519/00 ,  A61K31/513

CPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5377 ,  A61K45/06 ,  A61P9/04 ,  C07D519/00

摘要： The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.